Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston Scientific’s Lotus TAVR Gets Boost From REPRISE II And UK Series

This article was originally published in Clinica

Executive Summary

Boston Scientific’s Lotus transcatheter aortic valve replacement system demonstrated favorable outcomes in the REPRISE II trial and a 228-case series in the UK.

You may also be interested in...



OUS Approvals Analysis: BSX, Edwards Score New CE Marks In TAVR Battlefield; Chinese DES Advances In Asia

September's list of devices approved outside the US include a new transcatheter aortic valve in Europe, two orthopedic devices and a gynecology device in Australia, and a drug-eluting stent in Pakistan.

Boston Sci Recalls Some Lotus Valves After 3 Deaths

The company is recalling unused valves made before March 2016, which use a component that may break during deployment. Three patients have died of hemorrhage caused by the breakage.

Abbott Launches REPAIR MR Trial To Bring MitraClip To More Patients

The 500-patient REPAIR MR trial will evaluate Abbott’s MitraClip mitral valve repair device in patients who would face moderate risk during open heart surgery. MitraClip is currently approved only for patients who are not surgical candidates.

Topics

UsernamePublicRestriction

Register

MT103249

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel